This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bruker Corporation entered into an agreement to acquire Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $390 million. CI
Goldman Sachs Raises Price Target on Bruker to $74 From $66, Maintains Sell Rating MT
Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies CI
Bruker Corporation Enters into Term Loan Agreement with Bank of America, N.A CI
Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO CI
Bruker Corporation completed the acquisition of Chemspeed Technologies AG. CI
Transcript : Bruker Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM
UBS Raises Bruker Price Target to $102 From $94, Maintains Buy Rating MT
Transcript : Bruker Corporation Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:45 AM
Bruker to Acquire ELITechGroup for About $943 Million in Cash MT
Bruker Corporation entered into an agreement to acquire ELITech Group SAS from Tecfin S.À R.L. for approximately ?870 million. CI
Bruker Insider Sold Shares Worth $1,276,073, According to a Recent SEC Filing MT
Bruker Keeps Quarterly Dividend at $0.05 Per Share, Payable March 15 to Shareholders of Record on March 1 MT
Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024 CI
UBS Adjusts Bruker Price Target to $94 From $86, Maintains Buy Rating MT
TD Cowen Adjusts Bruker's Price Target to $84 From $75, Keeps Market Perform Rating MT
Stifel Adjusts Bruker's Price Target to $81 From $63, Keeps Hold Rating MT
Leerink Partners Adjusts Bruker's Price Target to $90 From $86, Keeps Outperform Rating MT
Citigroup Adjusts Bruker's Price Target to $95 From $80, Keeps Buy Rating MT
Jefferies Adjusts Bruker's Price Target to $90 From $72, Keeps Buy Rating MT
Goldman Sachs Adjusts Bruker's Price Target to $66 From $58, Keeps Sell Rating MT
JPMorgan Upgrades Bruker to Overweight From Neutral, Adjusts Price Target to $90 From $60 MT
Bruker Shares Rise Following Q4 Beat MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Bruker's Q4 Earnings Decline, Revenue Rises; Provides 2024 Guidance; Shares Gain 5% Pre-Bell MT
Chart Bruker Corporation
More charts
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. The Company’s BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. Its BSI Nano segment designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments. Its Bruker Energy & Supercon Technologies (BEST) segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and big science research. It offers scanning transmission electron microscopes (STEM). It also offers advanced research Raman microscopy systems.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
78.56 USD
Average target price
89.4 USD
Spread / Average Target
+13.80%
Consensus
  1. Stock Market
  2. Equities
  3. BRKR Stock
  4. News Bruker Corporation
  5. Earnings Flash (BRKR) BRUKER CORPORATION Reports Q1 EPS $0.49, vs. Street Est of $0.42